Last updated: February 20, 2026
What is NDC: 60687-0684?
The drug associated with NDC 60687-0684 is Sotyktu ( deucravacitinib ), a Janus kinase (JAK) inhibitor developed by Pfizer. It received FDA approval in September 2022 for moderate-to-severe plaque psoriasis. It operates as an oral therapy targeting TYK2, a subset of JAK enzymes, offering a novel mechanism within immunomodulatory treatments.
Market Landscape
Indications and Population
- Primary Indication: Moderate-to-severe plaque psoriasis
- Market Size: Estimated 7 million U.S. patients affected annually
- Treatments Available:
- Topicals
- Biologics (e.g., Humira, Skyrizi)
- Oral JAK inhibitors (e.g., Olumiant, Rinvoq)
Competitive Position
Sotyktu enters a competitive space with established biologics and oral JAK inhibitors. Key competitors include:
| Drug |
Class |
Approval Year |
Annual Sales (2021) |
Distribution Channels |
| Humira (adalimumab) |
Monoclonal antibody |
2002 |
$20.99B |
Specialty pharmacies & pharmacies |
| Skyrizi (risankizumab) |
IL-23 inhibitor |
2019 |
$3.02B |
Specialty pharmacies |
| Rinvoq (upadacitinib) |
JAK inhibitor |
2019 |
$2.2B |
Specialty pharmacies |
Market Penetration
- First-in-class TYK2 inhibitor
- Oral administration favored over injectable biologics
- Early uptake predicted to be high due to novel mechanism
Price Projections
Current Pricing
- List Price: Estimated at $1,200 per month ($14,400 annually)
- Average Selling Price (ASP): Approximate ASPs range between $1,100 and $1,300, factoring discounts and rebates
Revenue Estimations
Assuming the drug penetrates the psoriasis market at varying rates:
| Year |
Penetration Rate |
Prescriptions (Estimate) |
Revenue (USD) |
Notes |
| 2023 |
5% |
350,000 |
$4.2 billion |
Launch year, early adoption |
| 2024 |
15% |
1 million |
$12 billion |
Increased market penetration |
| 2025 |
25% |
1.75 million |
$21 billion |
Expanded use, payer coverage expansion |
Assumptions:
- Physician adoption rates remain steady
- Payer negotiations reduce net price by 15-20%
- Growth limited to psoriasis unless expanded for other indications
Discount and Rebate Considerations
- Average rebates for biologics and targeted oral agents hover around 30-35%
- Net prices are approximately 65-70% of list pricing
Future Price Trends
- Price stabilization expected as generic or biosimilar competition remains limited for small-molecule TYK2 inhibitors
- Market dynamics suggest slight decrease in net pricing over five years due to payer pressures
Regulatory and Market Factors
- Patent Position: Patent to extend until at least 2032
- Market Access: Payer negotiations critical; tiered formulary placement expected
- Potential for Indication Expansion: Risks and opportunities to treat other autoimmune disorders like psoriatic arthritis or Crohn’s disease
Key Market Risks
- Dominance of established biologic therapies may hinder rapid adoption
- Cost-effectiveness analyses could impact formulary access
- Competitive introduction of new JAK or TYK2 inhibitors
Summary of Market Outlook
| Aspect |
Insight |
| Market Size |
Approximately 7 million U.S. psoriasis patients; high unmet need in severe cases |
| Price Point |
List price around $1,200/month; net pricing about $780–$900/month post-discounts |
| Revenue Potential (2023–2025) |
Estimated $4.2B in 2023, rising to roughly $21B by 2025 with increased adoption |
Key Takeaways
- NDC 60687-0684 (Sotyktu) targets a competitive but expanding psoriasis market.
- Its oral route and novel TYK2 mechanism offer differentiation.
- Price projections indicate rapid revenue growth, contingent on market penetration and payer reimbursement.
- The product’s success depends on physician adoption and formulary positioning amidst entrenched biologics.
- Long-term pricing stability will depend on competitive pressures and indication expansion.
FAQs
Q1: What differentiates Sotyktu from other psoriasis treatments?
A1: It is a selective TYK2 inhibitor with oral administration, offering a non-injectable option with a novel mechanism.
Q2: How does the pricing compare to biologics?
A2: List price approximates biologic therapies but net prices are 20–30% lower due to rebates and discounts.
Q3: What is the potential for expanding indications?
A3: Promising, as autoimmune conditions like psoriatic arthritis or Crohn’s disease are under investigation, potentially broadening the market.
Q4: How might payer negotiations impact revenue?
A4: Rebates and formulary restrictions could reduce net price by up to 35%, affecting revenue forecasts.
Q5: When is the drug expected to reach peak sales?
A5: Likely between 2024 and 2025, as market penetration increases and additional indications are pursued.
References
- Food and Drug Administration. (2022). FDA approves Sotyktu for adults with psoriasis.
- IQVIA. (2022). Topicals and injectables market data.
- Pfizer Inc. Annual Reports. (2021-2022).
- EvaluatePharma. (2022). 2022 world drug sales.
- MarketWatch. (2022). Psoriasis therapeutics market forecast.
[1] U.S. Food and Drug Administration. (2022). FDA approves Sotyktu for adults with psoriasis.
